Jefferies Group’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $829K | Buy |
+10,030
| New | +$965K | 0.01% | 862 |
|
|
2022
Q1 | – | Sell |
-47,300
| Closed | -$6.13M | – | 1639 |
|
|
2021
Q4 | $6.13M | Sell |
47,300
-42,500
| -47% | -$4.96M | 0.04% | 406 |
|
|
2021
Q3 | $10.2M | Buy |
89,800
+83,578
| +1,343% | +$9.54M | 0.07% | 255 |
|
|
2021
Q2 | $644K | Sell |
6,222
-63,301
| -91% | -$5.97M | ﹤0.01% | 1104 |
|
|
2021
Q1 | $5.81M | Buy |
69,523
+50,915
| +274% | +$4.3M | 0.05% | 334 |
|
|
2020
Q4 | $1.7M | Sell |
18,608
-3,992
| -18% | -$331K | 0.01% | 764 |
|
|
2020
Q3 | $1.8M | Buy |
22,600
+12,600
| +126% | +$983K | 0.02% | 610 |
|
|
2020
Q2 | $691 | Buy |
10,000
+6,151
| +160% | +$437K | 0.01% | 838 |
|
|
2020
Q1 | $252K | Sell |
3,849
-23,229
| -86% | -$1.68M | ﹤0.01% | 1585 |
|
|
2019
Q4 | $2.11M | Buy |
27,078
+810
| +3% | +$63.2K | 0.02% | 1026 |
|
|
2019
Q3 | $1.93M | Buy |
26,268
+9,603
| +58% | +$675K | 0.01% | 1117 |
|
|
2019
Q2 | $1.03M | Sell |
16,665
-64,335
| -79% | -$3.89M | 0.01% | 1284 |
|
|
2019
Q1 | $5.17M | Buy |
81,000
+76,374
| +1,651% | +$4.36M | 0.04% | 432 |
|
|
2018
Q4 | $236K | Buy |
4,626
+2,121
| +85% | +$107K | ﹤0.01% | 1750 |
|
|
2018
Q3 | $145K | Buy |
2,505
+465
| +23% | +$22.7K | ﹤0.01% | 2164 |
|
|
2018
Q2 | $99K | Buy |
+2,040
| New | +$95.2K | ﹤0.01% | 2136 |
|
|
2018
Q1 | – | Sell |
-233,061
| Closed | -$8.76M | – | 2360 |
|
|
2017
Q4 | $8.76M | Buy |
233,061
+53,268
| +30% | +$1.95M | 0.04% | 345 |
|
|
2017
Q3 | $6.55M | Buy |
179,793
+136,152
| +312% | +$5.19M | 0.04% | 416 |
|
|
2017
Q2 | $1.72M | Buy |
43,641
+17,802
| +69% | +$650K | 0.01% | 1013 |
|
|
2017
Q1 | $810K | Buy |
25,839
+5,859
| +29% | +$183K | 0.01% | 1373 |
|
|
2016
Q4 | $624K | Sell |
19,980
-16,014
| -44% | -$519K | ﹤0.01% | 1500 |
|
|
2016
Q3 | $1.45M | Sell |
35,994
-140,745
| -80% | -$5.3M | 0.01% | 1091 |
|
|
2016
Q2 | $5.88M | Buy |
176,739
+57,462
| +48% | +$1.97M | 0.03% | 445 |
|
|
2016
Q1 | $3.51M | Buy |
119,277
+24,633
| +26% | +$680K | 0.02% | 619 |
|
|
2015
Q4 | $2.49M | Buy |
94,644
+85,644
| +952% | +$2.22M | 0.01% | 776 |
|
|
2015
Q3 | $213K | Sell |
9,000
-37,086
| -80% | -$895K | ﹤0.01% | 1910 |
|
|
2015
Q2 | $1.09M | Sell |
46,086
-210,468
| -82% | -$4.75M | 0.01% | 1203 |
|
|
2015
Q1 | $6.09M | Buy |
256,554
+153,384
| +149% | +$3.44M | 0.03% | 366 |
|
|
2014
Q4 | $2.19M | Buy |
+103,170
| New | +$2.07M | 0.01% | 679 |
|
|
2014
Q2 | – | Sell |
-94,860
| Closed | -$1.17M | – | 2151 |
|
|
2014
Q1 | $1.17M | Buy |
94,860
+60,606
| +177% | +$699K | 0.01% | 851 |
|
|
2013
Q4 | $375K | Sell |
34,254
-20,010
| -37% | -$226K | ﹤0.01% | 1274 |
|
|
2013
Q3 | $630K | Buy |
54,264
+12,696
| +31% | +$149K | 0.01% | 1106 |
|
|
2013
Q2 | $466K | Buy |
+41,568
| New | +$492K | 0.01% | 1098 |
|
Other funds holding EW
Jefferies Group's EW Position: Q3 2022 in Review
Jefferies Group opened a new position in Edwards Lifesciences (EW) in Q3 2022: 10,030 shares worth $829K. The stake represents 0.01% of the portfolio and ranks #862 among its holdings. This is a return to the name: Jefferies Group previously reported a position in EW as recently as Q4 2021.
Jefferies Group first reported a position in EW in Q2 2013 and has held it in 33 quarters since. The position peaked at $10.2M in Q3 2021. 1,246 funds tracked by Wall St. Rank hold EW as of Q3 2022.
- Jefferies Group held 10,030 shares of Edwards Lifesciences worth $829K as of Q3 2022.
- Edwards Lifesciences was a new Jefferies Group position in Q3 2022.
- Edwards Lifesciences made up 0.01% of Jefferies Group's portfolio in Q3 2022, its #862 holding.
- Jefferies Group first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 33 quarters since.
- Jefferies Group's Edwards Lifesciences position peaked at $10.2M in Q3 2021.
- 1,246 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2022.
Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.